EICHORPublic-registry trials using PD-1/VEGF Bispecific Antibody that Eichor's radar has found — 2 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) | Sichuan Baili Pharmaceutical Co., Ltd. | Non-squamous Non-small Cell Lung Cancer | PHASE2 / PHASE3 | 2 |
| A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) | Sichuan Baili Pharmaceutical Co., Ltd. | Squamous Non-small-cell Lung Cancer | PHASE2 / PHASE3 | 2 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
